hsa-miR-26a

ncRNA information

ncRNA name

hsa-miR-26a

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

No

Biomarker application

Upstream regulatory factors

Not available

Downstream target

HMGA2

Cancer information

Cancer name

Non-Small Cell Lung Carcinoma

Cancer site

Lung

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Up

Impact of overexpression of ncRNA on chemotherapy resistance

Down

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

MiR-26a is responsible for A549 cell sensitivity in the treatment of CDDP through regulating HMGA2-mediated E2F1-Akt pathway.

Tissue resource

human lung adenocarcinoma cell lines A549

human lung adenocarcinoma cisplatin-resistant cell lines A549/CDDP

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

the Peking Union Medical College

Country

China

Continent

Asia